Mpox Vaccine Safety

Institutional safety information on Mpox (JYNNEOS) vaccines. Clinical safety data, side effects, risk-based eligibility, and monitoring protocols from CDC and WHO sources.

Clinical Overview

Professional summary

Mpox is a viral zoonotic pathology induced by the Mpox virus, an orthopoxvirus. Transmission occurs through direct contact with infectious lesions, scabs, or systemic body fluids.

Clinical presentation typically includes a progressive rash that evolves through several stages. While statistically rare, severe systemic complications can occur, necessitating high-authority immunization protocols for high-risk cohorts.

Protects against Mpox virus through live, non-replicating technology.

Recommended primarily for cohorts at elevated risk of orthopoxvirus exposure.

Demonstrated clinical efficacy and established safety profile since development.

Authorized for intradermal and subcutaneous administration protocols.

Available Registry Modules

Vaccine modules

JYNNEOS

Bavarian Nordic | Orthopoxvirus Protocol

Formulation: Live, non-replicating viral node technology.
Authorization: Approved for individuals 18 years and older.
Dual-protection: Provides cross-protective immunity against smallpox.
Dosing logic: 2-dose series, administered 4 weeks apart.

Analyze intradermal vs subcutaneous administration logic on official nodes.

Eligibility & Schedules

Protocol triage

Primary Risk Cohorts

Documented Mpox exposure
High-probability exposure risk
Orthopoxvirus laboratory personnel

Clinical Risk Factors

Close contact with symptomatic cases
HCPs in acute Mpox care settings
Active regional outbreak zones

Contraindications

Anaphylaxis to previous JYNNEOS dose
Acute febrile illness state
Gestational/lactation status requires shared decision-making

Adverse Reaction Profile

Expected and critical events

Local Reactions

Injection site pain/erythema
Localized induration
Pruritus (Itching) at site

Systemic Profile

Generalized fatigue
Cephalalgia (Headache)
Myalgia
Nausea

Emergency Protocol

Clinical side effects are typically self-limiting, resolving within a 48-72 hour window post-administration.

Safety Metadata Analysis

Monitoring summary

2022

Crisis Validation

Millions

Doses Synchronized

High

Trial Efficacy

Institutional Surveillance

Continuous monitoring through VAERS and 2022 outbreak response data has established JYNNEOS as a safe protocol for individuals with immunocompromised profiles.

Verified Source: CDC / WHO

Last global review: September 1, 2025. Content verified by HCP Connect clinical editorial staff in alignment with 2026 safety protocols.